MedTrace Logo

PET/CT-Assessment of Liver Tumor Ablation

NCT02018107 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-03-26

Study results available
· View outcomes & findings →

Summary

In this research study, the investigators are evaluating whether ammonia PET scans or FDG PET perfusion scans are more useful in helping radiologists determine whether liver tumors were successfully destroyed by the heating or freezing procedures (ablations) than other scans currently available to radiologists, such as CT scans and MRI scans.

The currently available scan (usually a CT scan with contrast dye) is not always effective in showing how completely the tumor has been destroyed. The ammonia PET scan is a different way of looking at how much tumor has been destroyed. This study will compare the standard scan (CT scan) with the ammonia PET scan.

Conditions

  • Liver Tumor
  • Liver Neoplasms

Interventions

DIAGNOSTIC_TEST

N-13 ammonia or F-18 fluorodeoxyglucose

PET tracer

DIAGNOSTIC_TEST

PET scan

PET scan

Sponsors & Collaborators

Principal Investigators

  • Paul B. Shyn, M.D. · Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2018-02-16
Completion
2019-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02018107 on ClinicalTrials.gov